A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1558
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2017 A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. ET, MYSEC-PM, SMF
2017 A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. CALR, ET, PMF
2017 A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm. MPN
2017 A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. AEs, ET, ORR
2017 A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. CV, ECLAP, HU, PHL
2017 After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. ---
2017 Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. ALOX5
2017 Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. ---
2017 Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. BM, ET, MPNs, MVD, PMF
10  2017 Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. DXA, ET, HR-pQCT
11  2017 Bumpy road to the diagnosis of polycythaemia vera. ---
12  2017 Can pegylated interferon improve the outcome of polycythemia vera patients? HU, PEG-IFN
13  2017 Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. CI, CKD, eGFR, MPNs
14  2017 Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms. EMPs, ET, MPs, Ph-MPN, PMF, PMPs, RMPs
15  2017 Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. ET, MPN, PMF
16  2017 Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms. ET
17  2017 Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera. DM
18  2017 Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. ET, MPNs, PMF
19  2017 Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. ET, MF, MPN, MPNs
20  2017 Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. ET, hs-CRP, MPNs, PTX3
21  2017 Emerging treatments for classical myeloproliferative neoplasms. MPN
22  2017 Experience with ruxolitinib in the treatment of polycythaemia vera. HC, Hct
23  2017 Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. AVWS, ET
24  2017 FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. CMPD, ET, PMF
25  2017 Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms. ---
26  2017 Genetic Risk Assessment in Myeloproliferative Neoplasms. ET, PMF
27  2017 Imaging features of myeloproliferative neoplasms. CML, ET, MPNs, PMF
28  2017 Inflammation and myeloproliferative neoplasms. ET, hs-CRP, MF, MPN, PTX-3
29  2017 Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. CKD, CML, HCL, HCV, HUS, IFN, MS, TMA, TTP
30  2017 Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. ET, HPCs, PMF
31  2017 JAK2 inhibitors for myeloproliferative neoplasms: what is next? MF
32  2017 Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. MPNs
33  2017 Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. BAT, PRO
34  2017 Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ET, PMF
35  2017 Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm. BMAs, ET, JAK2, MF, MPNs
36  2017 Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. MF, MPNs, RUX
37  2017 MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera. MLF1IP
38  2017 Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. ET, PMF
39  2017 Monocytosis in polycythemia vera: Clinical and molecular correlates. CMML, MFFS, WHO
40  2017 Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. CMPNs, ET, PMF
41  2017 Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. ET, MF, MPN, RS, SMR
42  2017 Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. ET, IPF, IRF, MF, MPNs
43  2017 Polycythemia causing posterior segment vascular occlusions. CRAO
44  2017 Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. AVWS, ET
45  2017 Polycythemia Vera Management and Challenges in the Community Health Setting. ---
46  2017 Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. JAK2, MYSEC-PM, PPV-MF
47  2017 Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. BM, MFFS, MPN
48  2017 Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. ET, MPNs, Ph, PMF
49  2017 Progression of primary myelofibrosis to polycythemia vera: A case report. PMF
50  2017 Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. BM, CFC, EC, ET, PB, Ph-MPN, PMF
51  2017 Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches. JAK2
52  2017 pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms. ET, MPNs, PMF
53  2017 Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. PH
54  2017 Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. CALR, ET, MPN, PMF
55  2017 Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013. ET, MPNs, PMF
56  2017 Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. EPO, ET, MPN
57  2017 Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. BAT
58  2017 Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome. BCS, MPNs
59  2017 Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial. BAT, CMR, ET, HC, PMR
60  2017 Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. ET, MPN
61  2017 Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. ET, MPN, TN
62  2017 TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. ET, MPNs, PMF, SNPs
63  2017 The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. MF
64  2017 The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. CALR, DEX, GR, N-CALR, proEry
65  2017 The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). TSS-C
66  2017 The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. ET, MF, MPNs, QOL
67  2017 The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. ---
68  2017 The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. ET, MGUS, MM, MPN
69  2017 The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. ET, MF, PMF
70  2017 Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. ET, MPN, PMF
71  2017 Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera. IFN, pegIFNa, TTP
72  2017 VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. ET, MPNs, PMF
73  2017 Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera. ---
74  2016 A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. MF
75  2016 Acquired uniparental disomy of chromosome 9p in hematologic malignancies. aUPD, MPNs
76  2016 Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature. ALL
77  2016 Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon. ALL, HU
78  2016 Anesthetic management of a patient with polycythemia vera for neurosurgery. ---
79  2016 Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. ET, MPN, NGS, PMF
80  2016 Application of mutant JAK2V617F for in vitro generation of red blood cells. EPO, HSCs, mJAK2, RBCs, wJAK2
81  2016 Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. ET, MPNs, PMF, TNF-alpha
82  2016 Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. ET, MPN, PMF
83  2016 Blood donation and risk of polycythemia vera. CIs, ORs, SIRs
84  2016 Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm. ET, HEMILY, MF, MPN
85  2016 Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. MPN-SAF, PGIC, PSIS, QOL
86  2016 Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. ---
87  2016 Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms ET, Ph-negative MPNs, PMF
88  2016 Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms. ET, HPCs, HSCs, MF, MPN
89  2016 Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. CLL, ET, MPN, PMF
90  2016 Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. AP, MPN
91  2016 Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease. CVD, ET, MPD, PM
92  2016 Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. ET, MPNs
93  2016 Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. ET, NAP
94  2016 Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan. ET, IMF, MDS, MF
95  2016 Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. CALR, ET, PMF
96  2016 Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? ET, PMF
97  2016 Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms. ARMS, ET, HRM, MPN, PCR-RFLP, PMF
98  2016 Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders. DEGs, ES, ET, MPDs
99  2016 Construction of polycythemia vera protein interaction network and prediction of related biological functions. OMIM
100  2016 Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience. ET, PAH, PMF